You are about to leave the Clinical Value website now.
In this interview, Prof Chiu discusses the value of NGS testing to identify lung cancer driver mutations to detect and treat lung cancer early. He also highlights the challenges in…
Read Article
The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care. Access the…
Read Article
This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as an example.
Read Article
This report provides consensus recommendations for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations…
Read ArticleLung cancer is one of the most common forms of cancer, with 1.3 million people being diagnosed every year in APAC. Majority of these cases are diagnosed at late stages, when survival rates are low.
To ensure the best chances of survival, disease understanding, diagnostic testing, genomic profiling and clinical decision support solutions are key to early diagnosis and personalized treatment. Multidisciplinary partnership and innovation can provide the opportunity to improve the lives of millions of people around the world.
Diagnostic technologies are used across the entire patient journey of multiple disease states, and provide the tools to prevent, detect, and monitor the required interventions. Despite…
READ MORE